o Symptoms: dysuria, frequency, urgency, suprapubic pain ± haematuria
o Most common organisms: E. coli, Klebsiella, Proteus, Staphylococcus saprophyticus
o Diagnosis:
Urinalysis: leukocytes, nitrites (Gram-negative bacteria), ± blood
Urine culture: if recurrent, male, or complicated infection
o Treatment:
Empirical antibiotics (e.g. nitrofurantoin, trimethoprim)
Ensure adequate hydration
o Symptoms: fever, chills, flank or loin pain, vomiting
o Signs: costovertebral angle tenderness
o Urinalysis: pyuria, white cell casts (diagnostic), bacteriuria, ± haematuria
o Investigations:
Blood cultures if febrile
Imaging (e.g. ultrasound or CT) if atypical features, failure to improve
o Treatment:
Oral or IV antibiotics (e.g. ciprofloxacin, co-amoxiclav)
Admit if septic, vomiting, or pregnant
• Definition: Renal parenchymal damage due to vesicoureteric reflux (VUR) and recurrent UTIs, especially in children
• Pathophysiology:
o Congenital VUR → retrograde urine flow during voiding → pyelonephritis → renal scarring
o Leads to focal segmental glomerulosclerosis in advanced cases
• Clinical Features:
o Recurrent febrile UTIs in children
o Asymptomatic hypertension in older children/adults
o Proteinuria ± progressive CKD
• Diagnosis:
o Micturating cystourethrogram (MCUG): confirms VUR
o DMSA scan: detects renal scarring
o Renal ultrasound: small, scarred kidneys
• Management:
o Long-term antibiotic prophylaxis in selected cases
o Surgical correction in severe or persistent reflux
o Monitor BP and renal function
• Cause: Reactivation of haematogenous spread from primary TB (often pulmonary)
• Clinical Features:
o Sterile pyuria (WBCs in urine, but negative routine culture)
o Haematuria, dysuria, frequency
o Flank pain, low-grade fever, weight loss
o May cause non-functioning kidney, calcifications, strictures
• Investigations:
o Early morning urine: 3 consecutive samples for acid-fast bacilli (AFB) and TB culture (Lowenstein–Jensen medium)
o PCR for Mycobacterium tuberculosis may improve sensitivity
o IVU or CT urogram: cavitation, strictures, calcification ("putty kidney")
• Management:
o Standard anti-TB therapy (e.g. RIPE: rifampicin, isoniazid, pyrazinamide, ethambutol)
o Nephrectomy if severe damage/non-functioning kidney
————————————————————————————————————————————————————————————————————————————————————————————————————————-
Author & Educational Disclaimer
Author:
Dr Phillip Cockrell BM FRCP DipClinEd
Dr Phillip Cockrell is a UK Consultant Physician in Internal Medicine, currently working at Queen Alexandra Hospital, Portsmouth University Hospitals NHS Trust. He has previously worked as a registrar across Intensive Care Medicine, Gastroenterology, Cardiology, Stroke Medicine, Acute Medicine, and Respiratory Medicine.
He has held senior leadership roles including Associate Clinical Director of the Acute Medical Unit, Clinical Director of Internal Medicine, and Chief of Medicine. Dr Cockrell has over 15 years’ experience in postgraduate medical education, having lectured extensively across the MRCP syllabus and contributed to MRCP revision teaching and course development.
Dr Cockrell holds a Bachelor of Medicine (BM), Fellowship of the Royal College of Physicians (FRCP), and a Diploma in Clinical Education (DipClinEd). His teaching approach is based on structured consolidation of complex medical topics to support efficient and effective revision for postgraduate examinations.
Purpose of this content:
The material on this page is intended solely for educational purposes to support revision for the MRCP (UK) Part 1 examination. It reflects examination-relevant principles of internal medicine and is designed to aid learning and pattern recognition.
Medical disclaimer:
This content is designed for postgraduate medical examination revision and does not constitute medical advice, diagnosis, or treatment guidance and must not be used as a substitute for professional clinical judgement, local guidelines, or specialist consultation. Clinical decisions should always be made in the context of individual patient circumstances and current national guidance.